Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Roberts

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Arthritis and Rheumatism|June 26, 2008
Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcomeDavid Haynes, Tania Crotti, Helen Weedon, et al.
The Journal of Rheumatology|December 17, 2003
Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysisTania N Crotti, Michael J Ahern, Kylie Lange, et al.
Internal Medicine Journal|February 12, 2020
Scleroderma renal crisis: observations from the South Australian Scleroderma RegisterYassmin Khadra, Jennifer G Walker, Paul Hakendorf, et al.
International Journal of Rheumatic Diseases|February 14, 2012
South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcomeScott W Graf, Paul Hakendorf, Sue Lester, et al.
Pathology|September 24, 2005
Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosisJennifer G Walker, John Stirling, Dimitra Beroukas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KITCharles D Blanke, George D Demetri, Margaret von Mehren, et al.
Journal of Medicinal Chemistry|November 24, 2005
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptorsNigel P Dolman, Helen M Troop, Julia C A More, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2006
Molecular correlates of imatinib resistance in gastrointestinal stromal tumorsMichael C Heinrich, Christopher L Corless, Charles D Blanke, et al.
Ambio|December 30, 2022
The impacts of a global pandemic on the efficacy and stability of contemporary wildlife conservation: South Africa as a case studyDavid A Ehlers Smith, Yvette C Ehlers Smith, Harriet T Davies-Mostert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Arthritis and Rheumatism|June 26, 2008
Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcomeDavid Haynes, Tania Crotti, Helen Weedon, et al.
The Journal of Rheumatology|December 17, 2003
Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysisTania N Crotti, Michael J Ahern, Kylie Lange, et al.
Internal Medicine Journal|February 12, 2020
Scleroderma renal crisis: observations from the South Australian Scleroderma RegisterYassmin Khadra, Jennifer G Walker, Paul Hakendorf, et al.
International Journal of Rheumatic Diseases|February 14, 2012
South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcomeScott W Graf, Paul Hakendorf, Sue Lester, et al.
Pathology|September 24, 2005
Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosisJennifer G Walker, John Stirling, Dimitra Beroukas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KITCharles D Blanke, George D Demetri, Margaret von Mehren, et al.
Journal of Medicinal Chemistry|November 24, 2005
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptorsNigel P Dolman, Helen M Troop, Julia C A More, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2006
Molecular correlates of imatinib resistance in gastrointestinal stromal tumorsMichael C Heinrich, Christopher L Corless, Charles D Blanke, et al.
Ambio|December 30, 2022
The impacts of a global pandemic on the efficacy and stability of contemporary wildlife conservation: South Africa as a case studyDavid A Ehlers Smith, Yvette C Ehlers Smith, Harriet T Davies-Mostert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorMichael C Heinrich, Christopher L Corless, George D Demetri, et al.
Pageof 6